<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053963</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01803</org_study_id>
    <secondary_id>ADVL0212</secondary_id>
    <secondary_id>U01CA097452</secondary_id>
    <secondary_id>CDR0000269671</secondary_id>
    <nct_id>NCT00053963</nct_id>
    <nct_alias>NCT00069771</nct_alias>
  </id_info>
  <brief_title>FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia</brief_title>
  <official_title>A PHASE I STUDY OF DEPSIPEPTIDE (NSC#630176, IND# 51810) IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS AND LEUKEMIAS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of FR901228 in treating&#xD;
      children with refractory or recurrent solid tumors or leukemia. Drugs used in chemotherapy&#xD;
      use different ways to stop cancer cells from dividing so they stop growing or die&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose (MTD) of FR901228 (depsipeptide) in pediatric&#xD;
      patients with refractory or recurrent solid tumors.&#xD;
&#xD;
      II. Determine the dose-limiting toxic effects of this drug in these patients. III. Determine&#xD;
      the pharmacokinetics of this drug in these patients. IV. Assess tolerability of this drug at&#xD;
      the solid tumor MTD in patients with refractory or recurrent leukemia.&#xD;
&#xD;
      V. Determine, preliminarily, the antitumor activity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat&#xD;
      every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients with solid tumors receive escalating doses of FR901228 until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Cohorts of 3 patients (6 patients total) with leukemia receive FR901228 as above at the MTD.&#xD;
&#xD;
      Patients are followed for survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD, defined as that dose at which fewer than one-third of patients experience DLT, graded according to the NCI CTC version 2.0</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Blastic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Childhood Central Nervous System Germ Cell Tumor</condition>
  <condition>Childhood Choroid Plexus Tumor</condition>
  <condition>Childhood Chronic Myelogenous Leukemia</condition>
  <condition>Childhood Craniopharyngioma</condition>
  <condition>Childhood Grade I Meningioma</condition>
  <condition>Childhood Grade II Meningioma</condition>
  <condition>Childhood Grade III Meningioma</condition>
  <condition>Childhood High-grade Cerebral Astrocytoma</condition>
  <condition>Childhood Infratentorial Ependymoma</condition>
  <condition>Childhood Low-grade Cerebral Astrocytoma</condition>
  <condition>Childhood Spinal Cord Neoplasm</condition>
  <condition>Childhood Supratentorial Ependymoma</condition>
  <condition>Recurrent Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Childhood Acute Myeloid Leukemia</condition>
  <condition>Recurrent Childhood Brain Stem Glioma</condition>
  <condition>Recurrent Childhood Cerebellar Astrocytoma</condition>
  <condition>Recurrent Childhood Cerebral Astrocytoma</condition>
  <condition>Recurrent Childhood Ependymoma</condition>
  <condition>Recurrent Childhood Medulloblastoma</condition>
  <condition>Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor</condition>
  <condition>Recurrent Childhood Visual Pathway and Hypothalamic Glioma</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Relapsing Chronic Myelogenous Leukemia</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>romidepsin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>FK228</other_name>
    <other_name>FR901228</other_name>
    <other_name>Istodax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed malignancy&#xD;
&#xD;
               -  Extracranial solid tumors or brain tumors*&#xD;
&#xD;
               -  Diagnosis of leukemia allowed after maximum tolerated dose is determined,&#xD;
                  including any of the following:&#xD;
&#xD;
                    -  Acute lymphoblastic leukemia&#xD;
&#xD;
                    -  Acute myelogenous leukemia&#xD;
&#xD;
                    -  Chronic myelogenous leukemia in blast crisis&#xD;
&#xD;
          -  Disease must be refractory to conventional therapy or no effective conventional&#xD;
             therapy exists&#xD;
&#xD;
          -  CNS tumors resulting in neurological deficits must be stable for 2 weeks before study&#xD;
             entry&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100% (over 10 years old)&#xD;
&#xD;
          -  Performance status - Lansky 60-100% (10 years old and under)&#xD;
&#xD;
          -  At least 8 weeks&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3 (for solid tumor patients without bone&#xD;
             marrow involvement)&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3 (for solid tumor patients without bone marrow&#xD;
             involvement; platelet transfusion independent) OR 20,000/mm^3 (for leukemia patients;&#xD;
             platelet transfusion allowed)&#xD;
&#xD;
          -  Hemoglobin at least 8.0 g/dL (RBC transfusions allowed)&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT no greater than 5 times ULN&#xD;
&#xD;
          -  Albumin at least 2 g/dL&#xD;
&#xD;
          -  Glomerular filtration rate at least 70 mL/min&#xD;
&#xD;
          -  Creatinine based on age as follows:&#xD;
&#xD;
               -  No greater than 0.8 mg/dL (for patients 5 years of age and under)&#xD;
&#xD;
               -  No greater than 1.0 mg/dL (for patients 6 to 10 years of age)&#xD;
&#xD;
               -  No greater than 1.2 mg/dL (for patients 11 to 15 years of age)&#xD;
&#xD;
               -  No greater than 1.5 mg/dL (for patients over 15 years of age)&#xD;
&#xD;
          -  Calcium normal (with or without supplementation)&#xD;
&#xD;
          -  Shortening fraction at least 27% by echocardiogram OR ejection fraction at least 50%&#xD;
             by MUGA&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No uncontrolled cardiac arrhythmia&#xD;
&#xD;
          -  QTc less than 450 msec&#xD;
&#xD;
          -  No evidence of dyspnea at rest&#xD;
&#xD;
          -  No exercise intolerance&#xD;
&#xD;
          -  Pulse oximetry greater than 94%&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 1 month after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  Magnesium and potassium normal (with or without supplementation)&#xD;
&#xD;
          -  No uncontrolled seizure disorder&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No graft-vs-host disease&#xD;
&#xD;
          -  No seizure disorder unless well controlled and not on enzyme-inducing anticonvulsants&#xD;
&#xD;
          -  At least 1 week since prior growth factors&#xD;
&#xD;
          -  At least 3 weeks since prior biologic therapy or immunotherapy and recovered&#xD;
&#xD;
          -  At least 6 months since prior allogeneic stem cell transplantation&#xD;
&#xD;
          -  No concurrent routine prophylactic growth factors&#xD;
&#xD;
          -  At least 3 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas)&#xD;
             and recovered&#xD;
&#xD;
          -  No prior FR901228 (depsipeptide)&#xD;
&#xD;
          -  No other concurrent anticancer chemotherapy&#xD;
&#xD;
          -  Concurrent dexamethasone for CNS tumors allowed if on stable dose or decreasing dose&#xD;
             for at least 1 week before study entry&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior local palliative radiotherapy (small port)&#xD;
&#xD;
          -  At least 6 months since prior craniospinal radiotherapy or radiotherapy to at least&#xD;
             50% of pelvis&#xD;
&#xD;
          -  At least 6 weeks since other prior substantial bone marrow radiation&#xD;
&#xD;
          -  More than a 5 half-life washout period since prior and no concurrent medications&#xD;
             associated with prolongation of QTc interval&#xD;
&#xD;
          -  No concurrent enzyme-inducing anticonvulsants&#xD;
&#xD;
          -  No concurrent hydrochlorothiazide&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maryam Fouladi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Oncology Group</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Craniopharyngioma</mesh_term>
    <mesh_term>Adamantinoma</mesh_term>
    <mesh_term>Choroid Plexus Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Spinal Cord Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Romidepsin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

